VEGFA and colorectal carcinoma: Overall, the role of VEGF in the immune response and its critical role in CRC pathogenesis may represent a rationale to test whether the inhibition of the PD-L1/PD-1 pathway by immune checkpoint inhibitors in combination with anti-VEGF therapies enhances clinical response in mCRC patients.